This site is for U.S. Healthcare Professionals only.
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
Poster
Valemetostat
SOHO 2024 Annual Meeting | September 4-7, 2024
A phase 1 trial of valemetostat in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) or acute lymphocytic leukemia (ALL)
Poster
Quizartinib
SOHO 2024 Annual Meeting | September 4-7, 2024
QuANTUM-First trial: FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)–specific measurable residual disease (MRD) clearance assessed through induction and consolidation is associated with improved overall survival in newly diagnosed FLT3-ITD+ AML patients
Poster
Quizartinib
HOPA 2025 | April 9-12, 2025
QuANTUM-First: Effects of quizartinib on RFS, OS, CIR, and MRD in newly diagnosed patients with FMS-like tyrosine
kinase 3-internal tandem duplication–positive acute myeloid leukemia who received maintenance therapy
Poster
Quizartinib
EHA 2024 | June 13-16, 2024
QuANTUM-First: Efficacy by age in newly diagnosed patients with FMS-like tyrosine kinase 3-internal tandem duplication–positive acute myeloid leukemia
Poster
Quizartinib
SOHO 2024 Annual Meeting | September 4-7, 2024
QuANTUM-First: Efficacy by age in newly diagnosed patients with FMS-like tyrosine kinase 3-internal tandem duplication–positive acute myeloid leukemia
Oral
Quizartinib
EHA 2024 | June 13-16, 2024
QuANTUM-First: Efficacy in newly diagnosed patients with FMS-like tyrosine kinase 3-internal tandem duplication–positive acute myeloid leukemia who received continuation therapy
Poster
Quizartinib
EHA 2024 | June 13-16, 2024
QuANTUM-First: Patient-reported outcomes in newly diagnosed Italicize FLT3-ITD+ acute myeloid leukemia patients receiving standard chemotherapy plus quizartinib or placebo
Poster
Quizartinib
HOPA 2025 | April 9-12, 2025
QuANTUM-First: Safety by treatment phase and by age in newly diagnosed patients with FMS-like tyrosine kinase
3–internal tandem duplication (FLT3-ITD) positive acute myeloid leukemia
Poster
Quizartinib
ASCO 2025 | May 30-June 3,2025
QuANTUM-Wild: A phase 3, randomized, double-blind, placebo-controlled trial of quizartinib in combination with chemotherapy and as single-agent maintenance in FLT3-ITD–negative acute myeloid leukemia
Mini-Oral
Quizartinib
EHA 2025 | June 12-15, 2025
The combination of an FLT3-ITD, NPM1mut, and an epigenetic regulatory gene mutation confers unique sensitivity to quizartinib: Analysis from the QuANTUM-First trial
Pages:
1 2